ReadyGo Diagnostics Ltd. (ReadyGo™) and SureScreen Diagnostics Ltd. have announced a co-development agreement to create a revolutionary product for the drink spike testing market.
The partnership combines ReadyGo’s advanced Sampler technology and proprietary dried reagent technology with SureScreen’s proven assays for drug detection, providing an easy-to-use consumer testing solution.
The new testing assay will offer comprehensive drug testing in decentralised settings, with coverage for GHB, rohypnol, and ketamine. It will also provide rapid results in just a few minutes, making it easier for someone to make immediate decisions to prevent harm and keep individuals safe.
Designed for ease of use by non-specialised consumers, the test features simplified sample collection and processing, making it accessible for use in various environments such as bars, clubs, and other licensed premises.
Ben Cobb, CEO of ReadyGo Diagnostics Limited, stated, “This collaboration represents a significant step forward in our mission to provide innovative and accessible testing solutions to as many people as possible. By combining our innovative technology with SureScreen’s expertise in drug detection, we are creating a product that meets a growing and critical need for reliable drink spike testing for consumers who may be in vulnerable situations.”
George Newham, Research and Development Manager of SureScreen Diagnostics Limited, added, “We are excited to partner with ReadyGo Diagnostics on this important initiative. Our joint effort will deliver a powerful tool that enhances public safety and aligns with the evolving landscape of testing in licensed premises.”
This co-development initiative showcases the companies’ commitment to innovation and public health, with the goal of bringing to market a highly effective and user-friendly testing solution that can make a real difference in preventing drug-related harm.
For more information, please visit www.readygotest.com
About ReadyGo Diagnostics Ltd.
ReadyGo Diagnostics is a leader in the consumer-focused diagnostics industry, developing and commercializing breakthrough sample collection devices and diagnostic solutions. Their flagship molecular diagnostic platform, Geo, enables low-cost, decentralised results in under 30 minutes. Their innovative approach also includes the Snapshot, which merges efficient sample handling with an integrated molecular test, providing a comprehensive diagnostic solution in one device.
About SureScreen Diagnostics Ltd.
SureScreen Diagnostics Ltd. has been providing proactive, bespoke diagnostic solutions to organizations for over 27 years. Their state-of-the-art operational site in the UK allows for quick and reliable design, production, and services to customers throughout Europe and the rest of the world. They offer tailored services and products that provide fast, cost-effective, and accurate results, including world-first biodegradable tests. Their recent developments include producing and manufacturing lateral flow tests for Mpox and the first dual Influenza + Covid test approved for use in the UK.
For more information, please visit www.surescreen.com
Contacts
ReadyGo Diagnostics Ltd.
Ben Cobb, Chief Executive Officer
Ben Reed, Chief Commercial Officer
info@readygotest.com
SureScreen Diagnostics Ltd.
David Campbell, Director
George Newham, Research and Development Manager
Craig McMillan, Head of Sales and Marketing
info@surescreen.com
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.